763037006: Acalabrutinib (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Substance with effector mechanism of action (substance)\Enzyme inhibitor\Transferase inhibitor\Phosphotransferase inhibitor\Protein kinase inhibitor\Protein-tyrosine kinase inhibitor\Non-specific protein-tyrosine kinase inhibitor\Acalabrutinib

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Antineoplastic agent (substance)\Acalabrutinib

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\Organic compound\Organic cyclic compound\Heterocyclic compound\Benzimidazole (substance)\Acalabrutinib

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module

3637619010 Acalabrutinib en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

3637620016 Acalabrutinib (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Acalabrutinib	Is a	Benzimidazole (substance)	true	Inferred relationship	Some
Acalabrutinib	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Non-specific protein-tyrosine kinase inhibitor (disposition)	true	Inferred relationship	Some
Acalabrutinib	Is a	Non-specific protein-tyrosine kinase inhibitor	true	Inferred relationship	Some
Acalabrutinib	Is a	Enzyme inhibitor	false	Inferred relationship	Some
Acalabrutinib	Is a	Antineoplastic agent (substance)	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Product containing acalabrutinib (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Acalabrutinib	Inferred relationship	Some	1
Acalabrutinib-containing product in oral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Acalabrutinib	Inferred relationship	Some	1
Acalabrutinib only product	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Acalabrutinib	Inferred relationship	Some	1
Acalabrutinib only product in oral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Acalabrutinib	Inferred relationship	Some	1
Acalabrutinib 100 mg oral capsule	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Acalabrutinib	Inferred relationship	Some	1
Acalabrutinib 100 mg oral capsule	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Acalabrutinib	Inferred relationship	Some	1
Product containing precisely acalabrutinib 100 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Acalabrutinib	Inferred relationship	Some	1
Product containing precisely acalabrutinib 100 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Acalabrutinib	Inferred relationship	Some	1
Acalabrutinib maleate	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	True	Acalabrutinib	Inferred relationship	Some

This concept is not in any reference sets